DK231088D0
(da)
*
|
1988-04-28 |
1988-04-28 |
Ferrosan As |
Piperidinforbindelser, deres fremstilling og anvendelse
|
IE66332B1
(en)
*
|
1986-11-03 |
1995-12-27 |
Novo Nordisk As |
Piperidine compounds and their preparation and use
|
DK58291D0
(da)
*
|
1991-04-02 |
1991-04-02 |
Novo Nordisk As |
Krystalinsk stof og dets fremstilling
|
GB9209687D0
(en)
*
|
1992-05-06 |
1992-06-17 |
Smithkline Beecham Plc |
Novel process
|
US5258517A
(en)
*
|
1992-08-06 |
1993-11-02 |
Sepracor, Inc. |
Method of preparing optically pure precursors of paroxetine
|
US5276042A
(en)
*
|
1993-04-16 |
1994-01-04 |
Crenshaw Roger T |
Treatment of premature ejaculation
|
EP0639568A1
(en)
*
|
1993-08-19 |
1995-02-22 |
Novo Nordisk A/S |
Piperidine compounds, their preparation and use in the treatment of neurodegenerative disorders
|
GB9325644D0
(en)
*
|
1993-12-15 |
1994-02-16 |
Smithkline Beecham Plc |
Novel formulation
|
US20020086053A1
(en)
*
|
1993-12-15 |
2002-07-04 |
Smithkline Beecham Plc |
Formulations, tablets of paroxetine and process to prepare them
|
ES2102295B1
(es)
*
|
1994-03-18 |
1998-04-01 |
Ferrer Int |
Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
|
SK283608B6
(sk)
*
|
1995-02-06 |
2003-10-07 |
Smithkline Beecham Plc |
Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
|
US5856493A
(en)
*
|
1995-02-06 |
1999-01-05 |
Smithkline Beecham Corporation |
Process for making novel form of paroxeting hydrochloride anhydrate
|
GB9502297D0
(en)
|
1995-02-06 |
1995-03-29 |
Smithkline Beecham Plc |
Novel compound
|
ES2149726B1
(es)
*
|
1995-02-06 |
2001-06-16 |
Smithkline Beecham Plc |
Nuevos compuestos de paroxetina.
|
GB2297550C2
(en)
*
|
1995-02-06 |
1997-04-09 |
Smithkline Beecham Plc |
Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
GB9605828D0
(en)
*
|
1996-03-20 |
1996-05-22 |
Smithkline Beecham Plc |
Treatment method
|
CA2206592A1
(en)
*
|
1996-05-30 |
1997-11-30 |
Shu-Zhong Wang |
Method of producing amorphous paroxetine hydrochloride
|
JP3882224B2
(ja)
|
1996-05-31 |
2007-02-14 |
旭硝子株式会社 |
パロキセチンの製造方法
|
US5965555A
(en)
*
|
1996-06-07 |
1999-10-12 |
Hoechst Aktiengesellschaft |
Xanthine compounds having terminally animated alkynol side chains
|
EP0812827B1
(en)
|
1996-06-13 |
2009-09-02 |
Sumitomo Chemical Company, Limited |
Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation
|
HU221921B1
(hu)
*
|
1996-07-08 |
2003-02-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
|
EP0937152A2
(en)
*
|
1996-07-15 |
1999-08-25 |
Smithkline Beecham Plc |
Screening for and use of an esterase for a stereospecific resolution
|
US5672612A
(en)
*
|
1996-09-09 |
1997-09-30 |
Pentech Pharmaceuticals, Inc. |
Amorphous paroxetine composition
|
US6638948B1
(en)
*
|
1996-09-09 |
2003-10-28 |
Pentech Pharmaceuticals, Inc. |
Amorphous paroxetine composition
|
CA2193939C
(en)
*
|
1996-12-24 |
2002-02-12 |
K.S. Keshava Murthy |
Useful form of anhydrous paroxetine hydrochloride
|
WO1998056787A1
(en)
*
|
1997-06-10 |
1998-12-17 |
Synthon B.V. |
4-Phenylpiperidine compounds
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
GB9726907D0
(en)
*
|
1997-12-19 |
1998-02-18 |
Smithkline Beecham Plc |
Novel compounds
|
JP2002505254A
(ja)
*
|
1998-02-06 |
2002-02-19 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
パロキセチン塩
|
BR9908825A
(pt)
*
|
1998-03-16 |
2000-11-21 |
Smithkline Beecham Plc |
Forma cristalina de paroxetina
|
US6699882B2
(en)
|
1998-03-24 |
2004-03-02 |
Smithkline Beecham P.L.C. |
Paroxetine compositions
|
AU2003200534B2
(en)
*
|
1998-03-24 |
2004-12-02 |
Smithkline Beecham Plc |
Paroxetine compositions
|
GB9806312D0
(en)
*
|
1998-03-24 |
1998-05-20 |
Smithkline Beecham Plc |
Novel formulations
|
GB9808894D0
(en)
*
|
1998-04-25 |
1998-06-24 |
Smithkline Beecham Plc |
Novel compound
|
GB9808896D0
(en)
*
|
1998-04-25 |
1998-06-24 |
Smithkline Beecham Plc |
Novel compound
|
US6300343B1
(en)
|
1998-06-16 |
2001-10-09 |
Smithkline Beecham Corporation |
Method of treatment
|
GB9812941D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Smithkline Beecham Plc |
Method of treatment
|
GB9814316D0
(en)
*
|
1998-07-02 |
1998-09-02 |
Smithkline Beecham Plc |
Novel compounds
|
CH689805A8
(fr)
*
|
1998-07-02 |
2000-02-29 |
Smithkline Beecham Plc |
Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
|
ES2138937B1
(es)
|
1998-07-07 |
2000-10-01 |
Medichem Sa |
Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
|
ES2198940T3
(es)
*
|
1998-08-07 |
2004-02-01 |
Smithkline Beecham Plc |
Procedimiento para la preparacion de una forma anhidra no cristalina de hidrocloruro de paroxetina.
|
EP1102764A1
(en)
*
|
1998-08-08 |
2001-05-30 |
Smithkline Beecham Plc |
Paroxetine salts
|
GB9824298D0
(en)
*
|
1998-11-05 |
1998-12-30 |
Smithkline Beecham Plc |
Novel process
|
GB9826175D0
(en)
*
|
1998-11-28 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
GB9826176D0
(en)
*
|
1998-11-28 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
WO2000032594A1
(en)
*
|
1998-11-30 |
2000-06-08 |
Smithkline Beecham Plc |
Mixed paroxetine propan-2-ol solvates
|
GB9826171D0
(en)
*
|
1998-11-30 |
1999-01-20 |
Smithkline Beecham Plc |
Novel compounds
|
GB9826180D0
(en)
*
|
1998-11-30 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
GB9826178D0
(en)
*
|
1998-11-30 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
GB9826242D0
(en)
*
|
1998-11-30 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
GB9827387D0
(en)
*
|
1998-12-11 |
1999-02-03 |
Smithkline Beecham Plc |
Novel process
|
GB9828779D0
(en)
*
|
1998-12-29 |
1999-02-17 |
Smithkline Beecham Plc |
Novel process
|
GB9828781D0
(en)
*
|
1998-12-29 |
1999-02-17 |
Smithkline Beecham Plc |
Novel process
|
GB9828780D0
(en)
*
|
1998-12-29 |
1999-02-17 |
Smithkline Beecham Plc |
Novel process
|
GB9828767D0
(en)
*
|
1998-12-29 |
1999-02-17 |
Smithkline Beecham Plc |
Novel process
|
CA2367402C
(en)
*
|
1999-03-12 |
2010-11-23 |
Basf Aktiengesellschaft |
Stable pharmaceutical dosage form for paroxetine anhydrate
|
FR2791345B1
(fr)
*
|
1999-03-26 |
2001-05-04 |
Adir |
Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
GB9914585D0
(en)
*
|
1999-06-22 |
1999-08-25 |
Smithkline Beecham Plc |
Novel process
|
GB9914583D0
(en)
*
|
1999-06-22 |
1999-08-25 |
Smithkline Beecham Plc |
Novel process
|
KR100759159B1
(ko)
|
1999-07-01 |
2007-09-14 |
이탈파마코 에스.피.에이. |
파록세틴과 사이클로덱스트린 또는 사이클로덱스트린유도체의 컴플렉스
|
GB9916187D0
(en)
*
|
1999-07-09 |
1999-09-08 |
Smithkline Beecham Plc |
Novel process
|
GB9919052D0
(en)
*
|
1999-08-12 |
1999-10-13 |
Smithkline Beecham Plc |
Novel compound composition and process
|
GB9923446D0
(en)
*
|
1999-10-04 |
1999-12-08 |
Smithkline Beecham Plc |
Novel process
|
US6503927B1
(en)
|
1999-10-28 |
2003-01-07 |
Pentech Pharmaceuticals, Inc. |
Amorphous paroxetine composition
|
GB0003232D0
(en)
*
|
2000-02-11 |
2000-04-05 |
Smithkline Beecham Plc |
Novel composition
|
HU226912B1
(en)
*
|
2000-04-07 |
2010-03-01 |
Richter Gedeon Nyrt |
New paroxetin salt and medicament containing it
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
US6660298B1
(en)
*
|
2000-07-27 |
2003-12-09 |
Pentech Pharmaceuticals, Inc. |
Paroxetine tablets and capsules
|
US20030109577A1
(en)
*
|
2000-10-27 |
2003-06-12 |
Ken Liljegren |
Pharmaceutical composition containing citalopram
|
DE20100529U1
(de)
*
|
2001-01-11 |
2001-05-10 |
Synthon Bv |
Pharmazeutische Tablette umfassend Paroxetinmesylat
|
US6720003B2
(en)
|
2001-02-16 |
2004-04-13 |
Andrx Corporation |
Serotonin reuptake inhibitor formulations
|
US6610326B2
(en)
|
2001-02-16 |
2003-08-26 |
Andrx Corporation |
Divalproex sodium tablets
|
NL1017421C2
(nl)
|
2001-02-21 |
2002-01-15 |
Synthon Bv |
Werkwijze voor het vervaardigen van paroxetine.
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
AU2002318185A1
(en)
*
|
2001-06-13 |
2002-12-23 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of paroxetine substantially free of alkoxy impurities
|
IL159280A0
(en)
*
|
2001-06-14 |
2004-06-01 |
Teva Pharma |
A process for preparing paroxetine hcl which limits formation of pink colored compounds
|
BR0206164A
(pt)
*
|
2001-07-31 |
2003-10-28 |
Lundbeck & Co As H |
Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
|
EP1412350A1
(en)
*
|
2001-08-02 |
2004-04-28 |
Spurcourt Limited |
Paroxetine isethionate salt, process of preparation and use in the treatment of depression
|
JP2005501066A
(ja)
*
|
2001-08-09 |
2005-01-13 |
スミスクライン ビーチャム パブリック リミテッド カンパニー |
パロキセチンおよび医薬上許容されるグリチルリチン酸塩を含む組成物
|
NZ532432A
(en)
*
|
2001-10-22 |
2005-02-25 |
Synthon Bv |
N-formyl paroxetine compounds and their use in a synthetic route for obtaining paroxetine
|
IL162666A0
(en)
|
2001-12-28 |
2005-11-20 |
Teva Pharma |
A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
|
WO2003072104A1
(en)
*
|
2002-02-22 |
2003-09-04 |
Teva Pharmaceutical Industries Ltd. |
Preparation of paroxetine involving novel intermediates
|
AU2003217676B2
(en)
|
2002-02-22 |
2009-06-11 |
Takeda Pharmaceutical Company Limited |
Active agent delivery systems and methods for protecting and administering active agents
|
US6956121B2
(en)
*
|
2002-03-01 |
2005-10-18 |
Teva Pharmaceutical Industries Ltd. |
Preparation of paroxetine involving novel intermediates
|
UA77536C2
(en)
*
|
2002-07-03 |
2006-12-15 |
Lundbeck & Co As H |
Secondary aminoaniline piperidines as mch1 antagonists and their use
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
EP1555263A4
(en)
*
|
2002-09-19 |
2008-04-16 |
Sumitomo Chemical Co |
PROCESS FOR PRODUCING HYDROCHLORIDE OF PAROXETINE
|
US7329318B2
(en)
|
2002-09-19 |
2008-02-12 |
Sumitomo Chemical Company, Limited |
Methods of crystal precipitation
|
US20040220153A1
(en)
*
|
2002-09-24 |
2004-11-04 |
Jost-Price Edward Roydon |
Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
PL1507531T3
(pl)
*
|
2003-03-12 |
2007-06-29 |
Teva Pharma |
Trwałe kompozycje farmaceutyczne desloratadyny
|
US20060135547A1
(en)
*
|
2003-03-12 |
2006-06-22 |
Toth Zoltan G |
Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
|
WO2005065069A2
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
|
DK1691811T3
(da)
|
2003-12-11 |
2014-10-20 |
Sunovion Pharmaceuticals Inc |
Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
|
US20050154020A1
(en)
*
|
2004-01-14 |
2005-07-14 |
Synaptic Pharmaceutical Corporation |
4-Aryl piperidines
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
CA2567249A1
(en)
*
|
2004-04-19 |
2006-10-05 |
Jds Pharmaceuticals, Llc |
Lithium combinations, and uses related thereto
|
EP1745180A1
(en)
*
|
2004-04-29 |
2007-01-24 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
US20050266082A1
(en)
*
|
2004-05-26 |
2005-12-01 |
Patel Satishkumar A |
Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006018318A1
(en)
*
|
2004-08-18 |
2006-02-23 |
Synthon B.V. |
Liquid paroxetine compositions
|
EP1791531A1
(en)
*
|
2004-08-20 |
2007-06-06 |
Alpharma, Inc. |
Paroxetine formulations
|
KR100672184B1
(ko)
*
|
2004-09-21 |
2007-01-19 |
주식회사종근당 |
파록세틴의 콜린산 또는 콜린산 유도체 염
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
DE102004056398A1
(de)
*
|
2004-11-23 |
2006-05-24 |
Bayer Materialscience Ag |
Hydrolysestabile, hydrophobe, lösemittelfreie Polyole
|
US20060216345A1
(en)
*
|
2005-03-24 |
2006-09-28 |
Sun Pharmaceutical Industries Limited |
Oral pharmaceutical composition including paroxetine
|
EP1726591B1
(en)
*
|
2005-05-26 |
2008-09-10 |
Apotecnia , S.A. |
Process for manufacturing paroxetine hydrochloride hemihydrate
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
US20070042034A1
(en)
*
|
2005-07-22 |
2007-02-22 |
Myriad Genetics, Incorporated |
High drug load formulations and dosage forms
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
KR100591142B1
(ko)
*
|
2005-11-04 |
2006-06-20 |
지엘팜텍 주식회사 |
파록세틴을 활성물질로 함유하는 장용성 서방형 정제
|
WO2007054978A2
(en)
*
|
2005-11-10 |
2007-05-18 |
Jubilant Organosys Limited |
Process for preparing paroxetine hydrochloride hemihydrate
|
EP1948646A2
(en)
*
|
2005-11-14 |
2008-07-30 |
Auspex Pharmaceuticals Inc. |
Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
CN107235980A
(zh)
|
2006-05-04 |
2017-10-10 |
勃林格殷格翰国际有限公司 |
多晶型
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
WO2008012623A1
(en)
*
|
2006-07-25 |
2008-01-31 |
Pfizer Products Inc. |
Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
|
US20080033050A1
(en)
|
2006-08-04 |
2008-02-07 |
Richards Patricia Allison Tewe |
Method of treating thermoregulatory disfunction with paroxetine
|
EP2118074B1
(en)
|
2007-02-01 |
2014-01-22 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular diseases
|
US20080300258A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Souza Fabio Eduardo Silva |
Anhydrous ciprofloxacin hydrochloride
|
US9138430B2
(en)
*
|
2007-12-27 |
2015-09-22 |
Mylan Specialty L.P. |
Formulation and method for the release of paroxetine in the large intestine
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
DE102009030506A1
(de)
*
|
2008-06-30 |
2009-12-31 |
Borgwarner Inc., Auburn Hills |
Reibungsmaterialien
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
MX337352B
(es)
|
2009-03-18 |
2016-02-29 |
Resverlogix Corp |
Nuevos agentes anti-inflamatorios.
|
JP2010260826A
(ja)
*
|
2009-05-08 |
2010-11-18 |
Sumitomo Chemical Co Ltd |
パロキセチン塩酸塩半水和物の製造方法
|
ES2760917T3
(es)
|
2009-11-27 |
2020-05-18 |
Boehringer Ingelheim Int |
Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
|
BR112012028136A2
(pt)
|
2010-05-05 |
2016-08-09 |
Boehringer Ingelheim Int |
terapia de combinaçao
|
JP5700367B2
(ja)
*
|
2010-05-06 |
2015-04-15 |
高田製薬株式会社 |
パロキセチン含有フイルムコ−テイング経口製剤
|
ES2953123T3
(es)
|
2010-06-24 |
2023-11-08 |
Boehringer Ingelheim Int |
Terapia para la diabetes
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
JP2014508187A
(ja)
|
2011-03-17 |
2014-04-03 |
ルピン・リミテッド |
選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
|
GB201108345D0
(en)
*
|
2011-05-18 |
2011-06-29 |
Aesica Pharmaceuticals Ltd |
Process
|
ES2713566T3
(es)
|
2011-07-15 |
2019-05-22 |
Boehringer Ingelheim Int |
Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
|
CN102285973B
(zh)
*
|
2011-09-20 |
2013-03-06 |
海南美大制药有限公司 |
一种盐酸帕罗西汀化合物及其制法
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
AU2013204159B2
(en)
*
|
2013-03-15 |
2015-05-07 |
Bionomics Limited |
A Crystalline Form of an Anxiolytic Compound
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
CN104447714A
(zh)
*
|
2014-11-18 |
2015-03-25 |
成都医路康医学技术服务有限公司 |
一种盐酸帕罗西汀的生产工艺
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|